Finance Watch: US Biopharma Job Cuts Hit The East And West Coasts
Restructuring Edition: A new MassBio report showed Massachusetts biopharma employment dropped in 2025, echoing job cuts outlined in two recent California industry updates. Also, TScan and ArsenalBio reduced their workforces to focus on in vivo cell therapies.
Scrip - September 3, 2026

AbbVie’s Etentamig Suits Community Setting With Monthly Dosing, Low Toxicity
The BCMAxCD3-directed bispecific for myeloma would be late to the game, but it could address a significant uptake gap in immunotherapy treatment for the disease.
Scrip - September 3, 2026

Ionis’ Zanvastro Is First Disease-Modifying Drug For Alexander Disease
Only a few hundred individuals in the US are diagnosed with the progressive neurological disease; Ionis will focus on building disease awareness and diagnosis.
Scrip - September 3, 2026

UniQure Has Huntington’s Gene Therapy Approval In Its Sights Again
Its initial filing was rejected in April by the FDA’s now-departed Vinay Prasad but a new leadership agrees with UniQure that a new sham-controlled trial is not necessary raising hopes that its first product could soon be approaching the market.
Scrip - September 3, 2026

GSK Ups KRAS Efforts With Hutchmed Pact
Deal Snapshot: The UK major is linking up with the prolific Chinese R&D company to license an experimental antibody-drug conjugate that delivers a KRAS inhibitor to EGFR-expressing tumors.
Scrip - September 3, 2026

Ultragenyx’s Angelman Syndrome Failure Raises Big Questions About Its Pipeline
The Phase III failure of Ultragenyx’s apazunersen (GTX-102) in Angelman syndrome greatly diminishes investor enthusiasm over the biotech’s pipeline, sending shares crashing over 40%.
Scrip - September 3, 2026

Positive Early Data For NEC/Transgene’s Neoantigen Vaccine
Early clinical data for Transgene/NEC's individualized neoantigen therapeutic vaccine show 100% three-year disease-free survival in head and neck cancer patients.
Scrip - September 3, 2026

Chia Tai Tianqing’s First ADC Looking Good In HER2-Low Breast Cancer
World-first Phase III success for Chia Tai Tianqing's anti-HER2 bispecific in interim analysis for HER2-low breast cancer paves way for China approval filing.
Scrip - September 3, 2026

Head Start For Ivonescimab Over ADCs With OS Win Vs Keytruda In 1L NSCLC
The China-only, head-to-head Phase III HARMONi-2 trial with Akeso's ivonescimab has met the key secondary endpoint of overall survival in the first-line treatment of patients with PD-L1-positive NSCLC, with numerical findings to be presented at WCLC.
Scrip - September 3, 2026

Ablation Powers Medtronic’s Q1 As It Funnels Capital Into Robotics And Structural Heart
Medtronic opened fiscal 2027 with 13.7% Q1 growth powered by an 88% surge in cardiac ablation, and channeled the strength into a ~$700m Cornerstone robotics deal, an up-to-$80m Pi-Cardia structural-heart bet and raised guidance.
Medtech Insight - September 3, 2026

Pricing Patient Data: More Art Than Science, With Regulators Watching
As medtech companies race to feed patient data into diagnostic algorithms and AI models, valuation expert warn that pricing this intangible asset is still far more art than science — and in healthcare, getting the number wrong carries real regulatory risk.
Medtech Insight - September 3, 2026

Execs On The Move: August 24–28, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - September 3, 2026

Stryker Targets Rotator Cuff Augmentation With Early-Stage ZuriMED Buy
Stryker is acquiring ZuriMED and its FiberLocker System less than a year after US launch, betting that mechanical augmentation at the suture-tendon interface can address a retear rate that runs as high as 94% in some populations.
Medtech Insight - September 3, 2026

Adopting Surgical Intelligence Requires Trust Between Surgeons And Medtech
Operating rooms generate more data than ever — but adoption of surgical intelligence tools stalls when companies treat surgeons as users rather than co-designers. Trust, not technology, is the bottleneck.
Medtech Insight - September 3, 2026

Reckitt Seeks Open-Shelf Access For Pseudoephedrine In New Zealand
Reckitt has asked New Zealand's Medicines Classification Committee to let small packs of pseudoephedrine be sold without pharmacist involvement, arguing the drug will be the only effective oral decongestant left if phenylephrine goes.
HBW Insight - September 3, 2026

Dollar Shave Club Gets Premium Edge With Truly Beauty Deal
Dollar Shave Club's acquisition of Truly Beauty transforms the direct-to-consumer, value-priced brand into a multi-brand, dual-gender personal care platform with reach across both value and mass-premium consumers.
HBW Insight - September 3, 2026

Listing Requirement Potential Help For Faster Action By US FDA On Pesticide-Spiked Supplement
Undisclosed ingredients found in recalled product add to the range of substances the FDA and, in some cases, third-party testing have found in products labeled as supplements and available to US consumers.
HBW Insight - September 3, 2026

Mylan Conflict Challenge Derails September Humana Bellwether
Mylan has secured a temporary stay of Humana’s generic price-fixing bellwether after raising conflict allegations over special discovery master Lawrence Stengel, forcing a September 15 jury trial to be rescheduled.
Generics Bulletin - September 3, 2026

Viagra For Women: Daré Bioscience Focuses On Female Sexual Health With Topical Sildenafil
With no FDA-approved treatment for female sexual arousal disorder, Daré Bioscience is entering an unaddressed market by developing a 505(b)(2) sildenafil cream, while concurrently launching a 503B compounded version.
Generics Bulletin - September 3, 2026

Natco Rules Out Semaglutide Filings In Canada And Brazil
Natco has ruled out generic semaglutide filings in Canada and Brazil as competition intensifies in both markets, while its Indian brand faces aggressive pricing and limited profitability.
Generics Bulletin - September 3, 2026

Agentic AI And The Repricing Of Healthcare SaaS Models
Healthcare software beat earnings through H1 2026 and sold off anyway. Outcome Capital argues the market is repricing seat-based software, not management — and that healthcare, forced by regulators to codify how it works, is best placed to capture the agentic value replacing it.
In Vivo - September 2, 2026